Table 1 Summary of reported cases of ICI-related nephrotic syndrome
Authors | Age, sex | Underlying malignancies | Anti-PD-1 | Number of doses at onset | Renal pathological diagnosis | Creatinine (mg/dl) | Alb (g/dl) | Proteinuria (g/day) | Proteinuria (g/gCr) | Initial steroid dose | Dialysis |
|---|---|---|---|---|---|---|---|---|---|---|---|
Fadel, et al. 2009 | 60, M | Malignant melanoma | Ipilimumab | 2 | Lupus nephritis | 1.01 | 2.45 | 7.5 | NA | 1Â mg/kg/day | None |
Bickel et al. 2016 | 62, M | Malignant pleural mesothelioma | Pembrolizumab | 1(10 days from initial treatment) | MCD | NA | 1.5 | 19 | NA | 1Â mg/kg/day | None |
Daanen et al. 2017 | 62, M | RCC | Nivolumab | 4(7–8 weeks from initial treatment) | FSGS | 2.95 | 1.9 | 17 | NA | pulse 3days -> 60 mg/day | None |
Kitchlu, et al. 2017 -1 | 43, M | Hodgkin lymphoma | Pembrolizumab | 2(4 weeks from initial treatment) | MCD with acute tubular injury | 3.93 | 1.8 | 10.3 | NA | 2Â mg/kg/day | None |
Kitchlu, et al. 2017 -2 | 45, M | Malignant melanoma | Ipilimumab | 4(18 months into the treatment course) | MCD | 0.8 | 2.6 | 9.5 | NA | 1Â mg/kg/day | None |
Gao, et al. 2018 | 40, M | Hodgkin lymphoma | Camrelizumab | 3(65 days from initial treatment) | MCD | 0.9 | 2.1 | 30 | NA | 1Â mg/kg/day | None |
Mamlouk, et al. 2019-1 | 69, M | Malignant melanoma | Ipilimumab + Nivolumab | 2(6 weeks from initial treatment) | IgA nephropathy | 2.4 | NA | NA | 7.7 | 0.5 mg/kg/day | None |
Mamlouk, et al. 2019-2 | 60, F | RCC | Nivolumab | 6(16 weeks from initial treatment) | MN without PLA2R | NA | NA | NA | 9.7 | 1Â mg/kg/day | None |
Mamlouk, et al. 2019-3 | 63, M | Chondroma | Pembrolizumab | 6(18 weeks from initial treatment) | AA amyloidosis | 2.25 | NA | NA | 31 | 1Â mg/kg/day | None |
Glutsch, et al. 2019 | 68, M | Malignant melanoma | Pembrolizumab | 1(18 days from initial treatment) | MCD with acute tubular injury | 2.86 | 1.6 | NA | NA | 100Â mg/day | None |
Gallan, et al. 2019 | 71, F | Lung adenocarcinoma | Pembrolizumab | 10 months from initial treatment | Pauci-immune glomerulonephritis with crescents | 0.8 | NA | 5.5 | NA | NA | None |
Saito, et al. 2020 | 79, M | Lung adenocarcinoma | Pembrolizumab | 7(19-21weeks from initial treatment) | MCD | NA | 1.1 | NA | 13.82 | 40Â mg/day | None |
Ishibuchi, et al. 2020 | 70, M | Lung adenocarcinoma | Pembrolizumab | 5 months from initial treatment | NA | 1.63 | 1 | NA | 15.1 | 1.6Â mg/kg/day | Needed |
Chen, et al. 2021 | 74, M | Lung adenocarcinoma | Tislelizumab | 15(11 months from initial treatment) | MN(THSD7A positive) | 0.93 | 1.9 | 20.16 | NA | 60Â mg/day | None |
Kim, et al. 2021 | 46, F | Malignant melanoma | Pembrolizumab | 16 months from initial treatment | FSGS | 0.66 | 2.84 | NA | 3.277 | None | None |
Wakabayashi, et al. 2021 | 69, M | Lung adenocarcinoma | Nivolumab | 5 months from initial treatment | MN | 1.02 | 2.2 | NA | 13.3 | 0.8Â mg/kg/day | None |
The present case | 75, M | Malignant pleural mesothelioma | Ipilimumab + Nivolumab | 1(14 days from initial treatment) | MCD with AIN | 1.87 | 2 | 19.85 | NA | 1 mg/kg/day | Needed |